Abstract
BackgroundThe progressive neurodegenerative disorder Parkinson disease (PD) is well-established as the second most common neurodegenerative disease. Associations between the sequential risk of PD and gout have been addressed in other studies, but findings have been inconclusive. Accordingly, we executed the present study with the purpose of assessing PD risk in patients with gout.MethodsFrom Taiwan’s National Health Insurance Research Database, we identified the data of patients newly diagnosed as having gout between January 1, 2000 and December 1, 2000. A cohort of patients without gout, matched for sex and age, was constructed for comparison. Hazard ratios (HRs) and the incidence rate of subsequent PD were calculated for both cohorts and separately for male and female groups. The gout and comparison cohorts consisted of 7900 patients each.ResultsThe HR for PD was not significantly higher in the gout cohort compared with the control cohort (HR 1.01, 95% confidence interval [CI], 0.93–1.31, P = .268), even after adjustment for age, urbanization, monthly income, sex, and comorbidities. We did not observe gender differences in the gout–PD association (male: HR 1.01, 95% CI, 0.88–1.36, P = .400; female: HR 1.11, 95% CI, 0.84–1.46, P = .466).ConclusionsOur study identified that there was no protective effect of gout for the risk of PD in the Taiwanese population.
Highlights
The progressive neurodegenerative disorder Parkinson disease (PD) is well-established as the second most common neurodegenerative disease
The National Health Insurance Research Database (NHIRD), which is overseen by the National Health Research Institutes, comprises exhaustive information concerning clinic visits, including prescription details as well as diagnostic codes based on the A code and International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM)
Between the patients with gout and controls, the PD rate ratio (RR) was 1.36, with the RR remaining higher in patients with gout than in controls after stratification for age (≥65 or < 65 years) and sex (Table 3)
Summary
The progressive neurodegenerative disorder Parkinson disease (PD) is well-established as the second most common neurodegenerative disease. The well-known progressive neurodegenerative disorder Parkinson disease (PD) involves dopaminergic nigrostriatal neuron degeneration, which typically results in motor deficits. It has an estimated worldwide prevalence of 1 to 2% for individuals over the age of 65 years, rendering it the second most common neurodegenerative. The role of uric acid in the pathogenesis of PD has not been fully elucidated, there have been several studies demonstrating the associations between the serum UA concentrations [11, 12] and the risk of developing PD or the severity of the progressive symptoms in PD and Alzheimer’s disease [13]. Asian studies on gout and PD risk are, few [18]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
